 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys, announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. Citius pursuant to which it sold all of its rights to E7777 an engineered IL-2-diphtheria toxin fusion protein and certain related assets. Under the terms of agreement, Dr. Reddys will receive 